drugset / Trial / NCT04177095
Immune Monitoring to Facilitate Belatacept Monotherapy
Phase 4
Completed
17 enrolled
Massachusetts General Hospital
CareDx · collabTransplant Genomics, Inc. · collab
NaSingle-groupOpen-labelDiagnostic
Summary
* To determine the utility of novel blood-based immune monitoring tools (Allosure and Trugraf) to facilitate belatacept monotherapy. * To determine the percent of belatacept-treated renal transplant patients that can be safely converted to belatacept monotherapy.
Timeline
- Start
- 2020-02-11
- Primary completion
- 2021-09-30
- Completion
- 2023-06-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Everolimus | Small molecule | — | — |
| Subject | Mycophenolate Sodium | Unknown | — | — |
| Subject | Prednisone | Other / unclassified | — | — |
| Subject | Sirolimus | Small molecule | — | — |
| Background | Belatacept | Protein / enzyme biologic | — | — |